|Bid||16.70 x 900|
|Ask||16.73 x 1000|
|Day's range||16.56 - 17.27|
|52-week range||7.21 - 18.23|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||9.45|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Jul 2019|
|1y target est||14.28|
While Teva's focus in recent years has been on stabilizing revenue and EBITDA, analysts expect future attention to turn toward Teva's attractive brand assets. This shift could allow investors to benefit from accelerated product launches and reduced pipeline risks.
The far-right leader is on a mission to prevent “the worst crisis" in the country's history.